Navigation Links
Hospira Reports First-Quarter 2013 Results
Date:5/1/2013

er diluted share)$(0.95)Estimated amortization of intangible assets related tocertain acquisitions (mid-point of an estimated rangeof $0.29 to $0.33 per diluted share)$(0.31)Impairment of certain assets$(0.01)Estimated charges for certain quality and product-relatedmatters (mid-point of an estimated range of$0.33 to $0.41 per diluted share)$(0.37)Estimated charges related to capacity expansion(mid-point of an estimated range of $0.11 to $0.13per diluted share)$(0.12)Estimated acquisition and integration-related charges associated with the pending acquisition of an API-relatedbusiness from Orchid Chemicals & Pharmaceuticals(mid-point of an estimated range of $0.04 to $0.per diluted share)$(0.05)Other restructuring charges$(0.02)Diluted earnings per share -- GAAP$0.17- $0.27The adjusting items are shown net of tax in aggregate of $128 million, which is calculated for the specified adjustments stated above, based on the statutory tax rates in the various tax jurisdictions in which the items are expected to occur.

The company projects that cash flow from operations in 2013 will be between $200 million and $250 million. Depreciation and amortization is expected to be between $255 million and $275 million, and capital expenditures are projected to range between $425 million and $475 million.

*Use of Non-GAAP Financial MeasuresAdjusted* measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K furnished to the Securities and Exchange Commission on the date of this press release.

Webcast/Complementary MaterialHospira will hold a conference call for investors and media at 8 a.m. Central time on Wednesday, May 1, 2013. A live webcast of the conference call will be av
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Hospira Reports Third-Quarter 2012 Results
11. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- ResMed Inc. (NYSE: RMD ) today announced that ... June 30, 2015 results on Thursday, July 30, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)... July 2, 2015  The Green Exchange, Inc., the ... first HIPAA compliant mobile app that connects cannabis growers ... medical marijuana, announced today that their service provides the ... Meadow and more than half a dozen other delivery ... Loud Cannabis is unique in that it connects ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
... , April 27, 2010 Shire plc (LSE: ... it has received a Paragraph IV Notice Letter from Anchen,Pharmaceuticals, ... Application ("ANDA") for a generic version of Shire,s 1 mg, ... tablets, INTUNIV(TM).,Shire had previously reported in March 2010 ...
... April 27 For a second consecutive year, following the ... Auto Thefts) is cautioning Michigan drivers, and now auto dealers ... theft-related crimes.   , , ... increased vehicle security features, and the continuing success of Michigan ...
Cached Medicine Technology:Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 2Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 3H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 2H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 3
(Date:7/4/2015)... ... July 04, 2015 , ... Earlier in 2015, on ... an annual member survey , detailing the most common plastic surgery and minimally ... that raw data down into charts detailing demographic trends and regional preferences. With ...
(Date:7/3/2015)... ... ... Bank will hopefully be getting a large donation of canned food items at the ... are making it their mission to collect as many canned items as possible. Donations do ... public as well. As part of the canned food drive, these local chiropractors will be ...
(Date:7/3/2015)... ... 2015 , ... Scientists at several top US cancer centers believe they now ... Click here to read the complete story , just posted on the Surviving ... Medical Center, and New York University exposed mice with a mutation on the tumor ...
(Date:7/3/2015)... ... 2015 , ... The Erie County Bar Association Institute of ... Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law Offices. ... these types of cases. , Each year, New York State residents are hospitalized ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency ... named Mariah N. Manzanares, MD as the new Medical Director of its Frisco facility. ... director of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3
... 1,000 Reported Incidents, Caregivers Call for Comprehensive Process to Verify Signatures ... 31 Home care workers called for a hand-examination of each ... union, saying they had been subjected to lies, coercion, and fraud. ... the Service Employees International Union, United Healthcare Workers - West (SEIU-UHW), ...
... ... ... -- TDI, a leading provider of agent productivity solutions for contact centers, announced today that ... healthcare systems provider to the Greater New Orleans area. , , , , ,As an ...
... , , , ... HSP ), the world leader in generic injectable pharmaceuticals, today announced ... company,s applications for six new presentations of therapeutic heparin in single- ... to prevent clot formation in central venous catheters and for anticoagulant ...
... , , , CHADDS FORD, Pa., Aug. ... will present at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. ... Endo, will review the company,s products and development programs. , , ... website at www.endo.com under the investors section. ...
... , BERWYN, Pa., Aug. 31 Encorium ... clinical research organization (CRO) conducting studies in over 30 countries for ... that on August 25, 2009, it received a letter from The ... 10-Q for the period ended June 30, 2009, NASDAQ has determined ...
... , , , ... (the "Company") today announced that, at the Company,s 2009 Annual Meeting ... re-elect by an overwhelming majority all of the Company,s nominees to ... meeting were 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding ...
Cached Medicine News:Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:TDI Announces New Reseller Agreement With Executone 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: